Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia
2010; Karger Publishers; Volume: 225; Issue: 2 Linguagem: Inglês
10.1159/000317908
ISSN1423-0267
AutoresÂngela Carneiro, Rufino Silva, Maria J. Veludo, Augusto Barbosa, José M. Ruiz‐Moreno, Manuel Falcão, Elisete Brandão, Fernando Falcão‐Reis,
Tópico(s)Glaucoma and retinal disorders
Resumo<i>Aim:</i> Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM). <i>Methods:</i> Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted ≧3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly. <i>Results:</i> Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements ≧15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered. <i>Conclusion:</i> Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are encouraging. This treatment may constitute the only option for some of these patients.
Referência(s)